Form 4: Alkermes EVP R&D Exercises Options, Sells Shares

Alkermes' EVP R&D and Chief Medical Officer, Craig C. Hopkinson, exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.

Summary

• Craig C. Hopkinson, Executive Vice President of Research & Development and Chief Medical Officer of Alkermes plc, engaged in transactions involving the company's ordinary shares.
• On November 3, 2025, Hopkinson exercised employee stock options to acquire 5,000 ordinary shares at an exercise price of $19.34 per share.
• Following the option exercise, he sold 9,000 ordinary shares at a weighted average price of $30.3824 per share. The sale prices ranged from $30.34 to $30.56.
• Both the option exercise and the subsequent sale were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Hopkinson on March 14, 2025.
• After these transactions, Hopkinson directly beneficially owns 69,740 ordinary shares and 40,104 employee stock options.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 plan. While there's a net reduction in direct share ownership, the transactions were profitable for the insider, which can be seen as a minor positive, leading to a slightly positive to neutral sentiment.

Positives

• The insider's sale price of $30.3824 is significantly higher than the option exercise price of $19.34, indicating a profitable transaction for the executive.
• The transactions were executed under a Rule 10b5-1 trading plan, which provides transparency and reduces concerns about opportunistic insider trading.

Negatives

• There was a net reduction of 4,000 ordinary shares in the direct beneficial ownership of the executive (9,000 shares sold minus 5,000 shares acquired).

Industry Context

This filing details routine insider trading activity, specifically an executive's exercise of stock options and subsequent sale of shares. Such transactions are common in the pharmaceutical and biotechnology industries as part of executive compensation and personal financial planning, often managed through Rule 10b5-1 plans.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership and trading activities, which can influence investor confidence.
• Employees: Reflects standard executive compensation practices involving stock options as part of a broader compensation package.

Key Dates

Recommendation

This Form 4 details routine insider transactions (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 trading plan. Such transactions typically do not signal a fundamental change in the company's prospects or warrant a change in investment recommendation. The net sale of shares is part of a pre-planned liquidity event, not necessarily a bearish signal. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter a prior investment thesis.

Keywords

Alkermes, ALKS, insider trading, stock options, share sale, executive compensation, Form 4, Rule 10b5-1